A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CB03-154 in Healthy Participants in Australia

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2022
CB03-154 is an investigational drug developed by Shanghai Zhimeng Biopharma Inc. for the treatment of Epilepsy.
Epistemonikos ID: ba1c0f14993901ce73b9109cfe0ce9740ed1e2ec
First added on: May 13, 2024